UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

The lancet respiratory medicine, 2016-10, Vol.4 (10), p.781-796

2016

Volltextzugriff (PDF)

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids

Journal of allergy and clinical immunology, 2013-09, Vol.132 (3), p.567-574.e12

2013

Volltextzugriff (PDF)

Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)

Clinical and translational allergy, 2022-07, Vol.12 (7), p.e12176-n/a

2022

Volltextzugriff (PDF)

Comparability Considerations and Challenges for Expedited Development Programs for Biological Products

Drugs in R&D, 2020-12, Vol.20 (4), p.301-306

2020

Volltextzugriff (PDF)

Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor

Clinical and translational science, 2021-09, Vol.14 (5), p.1945-1954

2021

Volltextzugriff (PDF)

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

Thorax, 2015-08, Vol.70 (8), p.748-756

2015

Volltextzugriff (PDF)

Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies

mAbs, 2012-11, Vol.4 (6), p.724-731

2012

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma

Journal of clinical pharmacology, 2022-07, Vol.62 (7), p.905-917

2022

Volltextzugriff (PDF)

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids

Respiratory medicine, 2018-01, Vol.134, p.143-149

2018

Volltextzugriff (PDF)

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies

Trends in biotechnology (Regular ed.), 2010-10, Vol.28 (10), p.509-516

2010

Volltextzugriff (PDF)

A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)

Clinical and experimental allergy, 2020-12, Vol.50 (12), p.1342-1351

2020

Volltextzugriff (PDF)

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production

Science translational medicine, 2014-07, Vol.6 (243), p.243ra85

2014

Volltextzugriff (PDF)

Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps

Pulmonary pharmacology & therapeutics, 2021-12, Vol.71, p.102080-102080, Article 102080

2021

Volltextzugriff (PDF)

A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers

Advances in therapy, 2017-09, Vol.34 (9), p.2071-2082

2017

Volltextzugriff (PDF)

Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma

Pulmonary pharmacology & therapeutics, 2017-10, Vol.46, p.88-98

2017

Volltextzugriff (PDF)

Effect of the MDR1 C3435T Variant and P-Glycoprotein Induction on Dicloxacillin Pharmacokinetics

Journal of clinical pharmacology, 2005-04, Vol.45 (4), p.411-421

2005

Volltextzugriff (PDF)

Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy

The AAPS journal, 2013-04, Vol.15 (2), p.559-570

2013

Volltextzugriff (PDF)

Use of Quantitative Pharmacology in the Development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody

The AAPS journal, 2008-06, Vol.10 (2), p.425-430, Article 425

2008

Volltextzugriff (PDF)

Functional Characterization of Monocarboxylic Acid, Large Neutral Amino Acid, Bile Acid and Peptide Transporters, and P-Glycoprotein in MDCK and Caco-2 Cells

Journal of pharmaceutical sciences, 2002-12, Vol.91 (12), p.2622-2635

2002

Volltextzugriff (PDF)

The banded microstructure of sheared liquid-crystalline polymers

Polymer (Guildford), 1995-04, Vol.36 (9), p.1731-1741

1995

Volltextzugriff (PDF)

Comparison of bidirectional cephalexin transport across MDCK and Caco-2 cell monolayers: Interactions with peptide transporters

Pharmaceutical research, 2002, Vol.19 (1), p.27-33

2002

Volltextzugriff (PDF)

Monoclonal Antibodies: From Structure to Therapeutic Application

Pharmaceutical Biotechnology, 2019, p.151-190

2019

Volltextzugriff (PDF)

Evidence-Based Psychosocial Treatments for Children and Adolescents Exposed to Traumatic Events

Journal of clinical child and adolescent psychology, 2008-01, Vol.37 (1), p.156-183

2008

Volltextzugriff (PDF)

Diverging and Converging: Integrative Insights on a Paradox Meta-perspective

The Academy of Management annals, 2016-01, Vol.10 (1), p.173-182

2016

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(55)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids

Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)

Comparability Considerations and Challenges for Expedited Development Programs for Biological Products

Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor

Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration

Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies

Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies

Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma

Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies

A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production

Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps

A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers

Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma

Effect of the MDR1 C3435T Variant and P-Glycoprotein Induction on Dicloxacillin Pharmacokinetics

Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy

Use of Quantitative Pharmacology in the Development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody

Functional Characterization of Monocarboxylic Acid, Large Neutral Amino Acid, Bile Acid and Peptide Transporters, and P-Glycoprotein in MDCK and Caco-2 Cells

The banded microstructure of sheared liquid-crystalline polymers

Comparison of bidirectional cephalexin transport across MDCK and Caco-2 cell monolayers: Interactions with peptide transporters

Monoclonal Antibodies: From Structure to Therapeutic Application

Evidence-Based Psychosocial Treatments for Children and Adolescents Exposed to Traumatic Events

Diverging and Converging: Integrative Insights on a Paradox Meta-perspective

Suchergebnisse filtern